Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1635 1636 1645 1657 1674
This examiner grants 72% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19460949 | COMPOSITIONS AND METHODS FOR PROGRAMMED DEATH LIGAND RECEPTOR (PD-L1) EXPRESSION | Non-Final OA | NOVO NORDISK A/S |
| 18021469 | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | Non-Final OA | The Regents of the University of California |
| 17636481 | METHOD OF MODULATING ADIPOSITY | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18577903 | Yeast Single Nucleotide Polymorphisms for Industrially Relevant Phenotypes | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 18069387 | ENGINEERED NUCLEASES AND METHODS OF USE THEREOF | Final Rejection | Massachusetts Institute of Technology |
| 17910497 | NOVEL CAS ENZYMES AND METHODS OF PROFILING SPECIFICITY AND ACTIVITY | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18490131 | ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT | Non-Final OA | The Board of Regents of The University of Texas System |
| 18471280 | COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA | Non-Final OA | The Board of Regents of The University of Texas System |
| 18019720 | Human XIST Antisense Oligonucleotides for X Reactivation Therapy | Non-Final OA | The General Hospital Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy